Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry

Tumor Biology

Volumn 26, Issue 1, 2005, Pages 25-30

  Corzo, Cristina ^a,c   Tusquets, Ignacio ^b   Salido, Marta ^a   Corominas, Josep Maria ^a   Bellet, Meritxell ^b   Suarez, Marta ^b   Baró, Teresa ^a   Fabregat, Xavier ^b   Serrano, Sergio ^a   Solé, Francesc ^a  

^a HOSPITAL DEL MAR   (Spain)

^b Del Mar University   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Epidermal growth factor receptor; Fluorescence in situ hybridization; HER1; Immunohistochemistry; Locally advanced breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PARAFFIN; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CHROMOSOME 7; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR BIOPSY;

EID: 20244379711     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084183     Document Type: Article

References (30)

1. Baselga J: Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol 2001;19:41-44.
2. Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32-40.
3. Suo Z, Risberg B, Kalsson MG, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. C-erbB2 and c-erbB4 receptors have different effects on survival. J Pathol 2002;196:17-25.
4. Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994;19:3-9.
5. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
6. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ: Frequent expression of mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-5539.
7. Stern DF, Hare DL, Cecchini MA, Weinberg RA: Construction of a novel oncogene based on synthetic sequences encoding epidermal growth factor. Science 1987;16:321-324.
8. Klijn JG, Berns PM, Schmitz J, Foekens JA: The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: A review on 5232 patients. Endocr Rev 1987;13:3-17.
9. Kersting C, Tidow N, Schmidt H, Liedtke C, Neumann J, Boecker W, van Diest PJ, Brandt B, Buerger H: Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84:582-587.
10. Rude Voldborg B, Damstrup L, Spang-Thomsen M, Skovgaard Poulsen H: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197-1206.
11. Morris C: The role of EGFR-directed therapy in the treatment of the breast cancer. Breast Cancer Res Treat 2002;75:51-55.
12. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and a review of 3009 patients. Breast Cancer Res Treat 1994;29:41-49.
13. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA: The prognostic values of epidermal growth factor receptor (EGFR) in primary breast cancer: Results of a 10-year follow-up study. Cancer Res Treat 1994;29:73-83.
14. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063.
15. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermial growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
16. Ciardello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
17. Chen Z, Ke L, Yuan XH: Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000;20:747-753.
18. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914.
19. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 1995;267:1782-1788.
20. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004;10:658-667.
21. Sauer T, Beraki K, Jebsen PW, Naess O: Numerical abnormalities of chromosome 7 in interphase cell nuclei of breast carcinoma have no impact on immunohistochemically determined EGFR status. APMIS 1999;107:211-216.
22. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J: Amplification and deletion of topoisomerase IIα associate with ErbB2 amplification and effect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
23. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326.
24. Strayer DS, Shijun Y, Schwartz MS: Epidermal growth factor-like growth factor. Breast malignancies and other epithelial proliferations in transgenic mice. Lab Invest 1993;6:660-673.
25. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002;8:54-60.
26. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV: Epidermal growth factor receptor and HER2/neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-1855.
27. Pawlwski V, Révillion F, Hebbar M, Hornez L, Peyrat JP: Prognostic value of type I growth factor receptor in a large series of human primary breast cancers quantified with real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-4225.
28. Baselga J: Combined anti-EGF receptor and anti-Her2 receptor therapy in breast cancer: A promising strategy ready for clinical testing. Ann Oncol 2002;13:8-9.
29. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y: Prognostic value of the combination of epidermal growth factor receptor and c-erbB2 in breast cancer. Surgery 2003;133:219-221.
30. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002;8:3454-3460.